[Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled proliferation of plasma cells.
• Targeting key signaling pathways like mTORC2 and heat shock protein 90 (HSP90) offers potential therapeutic strategies for MM.
• Understanding the interplay between these pathways is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the combined effect of inhibiting the mTORC2 signaling pathway and heat shock protein 90 on multiple myeloma cell apoptosis.
• To elucidate the underlying molecular mechanisms driving apoptosis in MM cells under combined inhibition.

Main Methods:

• Utilized MTT assays to assess the proliferation of MM cell lines (U266, KM3) treated with Rapamycin, 17-AAG, and their combination.
• Employed flow cytometry to measure cell apoptosis and cell cycle distribution.
• Detected protein expression levels of p-AKT, AKT, and p-S6 using Western blotting.

Main Results:

• The combination of Rapamycin and 17-AAG demonstrated synergistic inhibition of MM cell proliferation compared to single agents.
• Both Rapamycin and 17-AAG induced G1 cell cycle arrest and apoptosis in MM cells.
• Combined inhibition of mTORC2 and HSP90 pathways led to AKT degradation and significantly enhanced MM cell apoptosis.

Conclusions:

• Simultaneous inhibition of mTORC2 and HSP90 pathways effectively induces apoptosis in multiple myeloma cells.
• This dual inhibition strategy, by decreasing AKT expression, presents a promising in vitro approach for MM treatment.